MOF materials as therapeutic agents, drug carriers, imaging agents and biosensors in cancer biomedicine: Recent advances and perspectives

A Bieniek, AP Terzyk, M Wiśniewski, K Roszek… - Progress in Materials …, 2021 - Elsevier
We summarize recent advances in application of MOFs as therapeutic agents, drug carriers,
imaging agents and biosensors in cancer biomedicine. A holistic perspective is adopted to …

Targeting telomeres and telomerase

A De Cian, L Lacroix, C Douarre, N Temime-Smaali… - Biochimie, 2008 - Elsevier
Telomeres and telomerase represent, at least in theory, an extremely attractive target for
cancer therapy. The objective of this review is to present the latest view on the mechanism …

New drugs are not enough-drug repositioning in oncology: An update

RG Armando, DLM Gomez… - … Journal of Oncology, 2020 - spandidos-publications.com
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that
are already known for use treating other diseases. The advantages of this are that several …

[HTML][HTML] The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers

Q Zhang, WW Chen, X Sun, D Qian… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Cancers are generally recognized as the leading cause of death and a predominant barrier
to prolonging life expectancy in both developed and developing countries. Emodin is a …

New organochalcogen multitarget drug: Synthesis and antioxidant and antitumoral activities of chalcogenozidovudine derivatives

D de Souza, DOC Mariano, F Nedel… - Journal of medicinal …, 2015 - ACS Publications
In this article we present the synthesis, characterization, and in vitro biological and
biochemical activities of new chalcogenozidovudine derivatives as antioxidant (inhibition of …

Repurposing of antimicrobial agents for cancer therapy: what do we know?

C Pfab, L Schnobrich, S Eldnasoury, A Gessner… - Cancers, 2021 - mdpi.com
Simple Summary Despite the leaps and bounds in the prevention and treatment of cancer, it
remains the second leading cause of death worldwide. A significant hurdle during cancer …

Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy

ER Scruggs, AJ Dirks Naylor - Pharmacology, 2008 - karger.com
Abstract Zidovudine (3-azido-3′-deoxythymidine), also referred to as azidothymidine (AZT),
has become an integral component in highly active antiretroviral therapy, and has also been …

Parathyroid carcinoma: a review

RP Owen, CE Silver, PK Pellitteri, AR Shaha… - Head & …, 2011 - Wiley Online Library
Background. Parathyroid carcinoma is a rare entity, comprising fewer than 1% of cases of
hyperparathyroidism. The disease generally presents with severe hyperparathyroidism and …

Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors

OA Olivero - Environmental and molecular mutagenesis, 2007 - Wiley Online Library
Nucleoside analogs were first approved by the US Food and Drug Administration for use
against HIV‐AIDS in 1987. Since then, these agents, now commonly referred to as …

Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood–brain barrier endothelial …

KR Manda, A Banerjee, WA Banks, N Ercal - Free Radical Biology and …, 2011 - Elsevier
The era of highly active antiretroviral therapy (HAART) has controlled AIDS and its related
disorders considerably; however, the prevalence of HIV-1-associated neurocognitive …